Global menu

Our global pages

Close

We acted as Revenio Group Corporation’s legal advisor in its acquisition of the CenterVue Group from Italy and the USA

  • Finland

    14-05-2019

    Revenio Group Corporation signed, on 13 April 2019, an agreement on the purchase of all shares of the Italian CenterVue SpA for an enterprise value (EV) of MEUR 59. The acquisition supports Revenio’s goal of strengthening its position as the global market leader in devices for the diagnostics and monitoring of the eye, and glaucoma in particular. The Italian CenterVue is a leading supplier of ophthalmic devices and its products complement Revenio’s product portfolio.

    The acquisition was completed on 30 April 2019. The product development centre of CenterVue’s optical products and software will remain in Italy also in future. Correspondingly, Revenio’s product development centre focusing on products and software related to tonometry will remain in Finland.

    Revenio Group Corporation’s Stock Exchange Release on the subject (in Finnish)

     

    Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy. Revenio’s core business is to develop and commercialize effective and easily adopted devices to assist in the diagnostics of glaucoma and its monitoring during treatment. In 2018, Revenio Group's net sales totalled EUR 30.7 million, with its net operating profit standing at 33.3%. Revenio Group Corporation is listed on Nasdaq Helsinki.

    For more information contact

    Harri Tolppanen, Partner

    Disclaimer

    This information is for guidance purposes only and should not be regarded as a substitute for taking legal advice. Please refer to the full terms and conditions on our website.

    < Go back